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Eliminating virally infected cells is an essential component of any HIV eradication strat-
egy. Radioimmunotherapy (RIT), a clinically established method for killing cells using 
radiolabeled antibodies, was recently applied to target HIV-1 gp41 antigen expressed 
on the surface of infected cells. Since gp41 expression by infected cells is likely down-
regulated in patients on antiretroviral therapy (ART), we evaluated the ability of RIT to kill 
ART-treated infected cells using both in vitro models and lymphocytes isolated from HIV-
infected subjects. Human peripheral blood mononuclear cells (PBMCs) were infected 
with HIV and cultured in the presence of two clinically relevant ART combinations. 
Scatchard analysis of the 2556 human monoclonal antibody to HIV gp41 binding to 
the infected and ART-treated cells demonstrated sufficient residual expression of gp41 
on the cell surface to warrant subsequent RIT. This is the first time the quantification of 
gp41 post-ART is being reported. Cells were then treated with Bismuth-213-labeled 
2556 antibody. Cell survival was quantified by Trypan blue and residual viremia by 
p24 ELISA. Cell surface gp41 expression was assessed by Scatchard analysis. The 
experiments were repeated using PBMCs isolated from blood specimens obtained from 
15 HIV-infected individuals: 10 on ART and 5 ART-naïve. We found that 213Bi-2556 killed 
ART-treated infected PBMCs and reduced viral production to undetectable levels. ART 
and RIT co-treatment was more effective at reducing viral load in vitro than either therapy 
alone, indicating that gp41 expression under ART was sufficient to allow 213Bi-2556 to 
deliver cytocidal doses of radiation to infected cells. This study provides proof of concept 
that 213Bi-2556 may represent an innovative and effective targeting method for killing 
HIV-infected cells treated with ART and supports continued development of 213Bi-2556 
for co-administration with ART toward an HIV eradication strategy.
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inTrODUcTiOn
HIV/AIDS continues to be an enormous global health burden with over 34 million infected people 
worldwide (WHO data). HIV-infected individuals now live much longer due to the suppression of 
the viral replication by antiretroviral therapy (ART). However, ART cannot kill infected cells, and 
HIV remains an incurable disease (1). Intensification of ART regimens failed to produce eradication 
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of residual HIV-infected cells both systemically and in the central 
nervous system (2, 3). Thus, any strategy for curing HIV must 
include a method to eliminate virally infected cells.
Radioimmunotherapy (RIT) is used in cancer treatment and 
is FDA-approved for treatment of non-Hodgkin’s lymphoma 
(4, 5). RIT uses monoclonal antibodies (mAbs) to target antigens 
over-expressed by tumor cells. The radiolabeled antibody acts as 
a homing device for the delivery of cytocidal ionizing radiation to 
cells expressing the targeted antigen. We have introduced RIT for 
a number of infectious diseases and demonstrated its feasibility 
for killing HIV-infected human cells in vivo (6, 7). Recently, we 
identified a fully human mAb 2556 directed toward a highly con-
served epitope on the gp41 transmembrane glycoprotein, which 
is exposed both on viral particles and on the surface of infected 
cells. The 2556 mAb bound to the immunodominant domain 
(cluster 1) of gp41 shared across all subtypes within HIV clades 
A to H and was selected for preclinical development because of its 
superior binding to the gp41 when compared to naturally occur-
ring antibodies in HIV-infected individuals. When radiolabeled 
with bismuth-213 (213Bi), an α-emitter with the 6–8 MeV energy 
of α-radiation, 213Bi-2556 killed HIV-infected human peripheral 
blood mononuclear cells (PBMCs) injected into SCID mice 
and produced no hematologic toxicity (8). Since the majority 
of HIV-infected individuals in the US are receiving ART and 
ART becomes more accessible to individuals worldwide, we have 
investigated the ability of 213Bi-2556 to kill HIV-infected cells from 
individuals on various ART regimens. Our results using ex vivo 
samples support further development of an RIT-based treatment 
for use with antiretroviral drugs toward HIV eradication.
MaTerials anD MeThODs
ethics statement
All healthy blood donors provided written informed consent. All 
patients in the study were HIV-infected adults who provided writ-
ten informed consent. The study was approved by the Montefiore 
Medical Center IRB #2011-1100.
compounds
Antiretroviral therapy drugs were selected to represent the three 
major ART classes typically prescribed for first-line therapy: 
nucleoside reverse transcriptase inhibitors (NRTIs), non- 
nucleoside reverse transcriptase inhibitors (NNRTIs), and pro-
tease inhibitors (PIs). The NIH AIDS Research and Reference 
Reagent Program provided all drugs, viral strains, and cell lines. 
The following four ART drugs were used: tenofovir (TFV, Cat. 
# 10199), emtricitabine (FTC, Cat. # 10071), efavirenz (EFV, 
Cat. # 4624), and atazanavir (ATZ) sulfate (Cat. # 10003). These 
compounds were dissolved in dimethyl sulfoxide (DMSO) to 
10 ng/mL, serially diluted into phosphate-buffered saline (PBS), 
and stocks frozen at −20°C at 10× the desired final concentra-
tion. The drugs were assessed individually and in two clinically 
relevant combinations TFV/FTC/EFV and TFV/FTC/ATZ 
as per the guidelines for ART (9). The following cell lines and 
biological reagents from the same source were used: the A3.01 
cell line, a human T-cell line derived from acute lymphoblastic 
leukemia (Cat. # 166, from Dr. Thomas Folks); the ACH-2 cell 
line (Cat.  #  349 from Dr. Thomas  Folks), an A3.01 subclone 
chronically infected with a single integrated copy of proviral LAV 
HIVIIIB; human recombinant IL-2 (Cat. # 136 from Dr. Maurice 
Gately); HIV-1 Ada-M (Cat. #416 from Dr. Howard Gendelman); 
and HIV-1 pNL4-3 (Cat. #114 from Dr. Malcolm Martin).
cellular Models of hiV infection
ACH-2 and A3.01 cells were cultured in RPMI 1640 (Hyclone) 
with 2-mM glutamine, 10-mM HEPES, 1% (v/v) penicillin–
streptomycin (Gibco-Invitrogen), and 10% (v/v) heat-inactivated 
fetal bovine serum (Hyclone). Phorbol 12-myristate 13-acetate 
(PMA, Sigma) was added to media containing 106  cells/mL at 
200 nM for 48 h to induce high viral production in ACH-2 cells 
(10). Activated ACH-2 cells were combined with the uninfected 
parental A3.01 line at 1:10 to simulate 10% infection in a sample. 
Human PBMCs were isolated using a Ficoll-Hypaque density 
gradient from healthy HIV-seronegative donors blood purchased 
from the New York Blood Center (New York, NY, USA) and 
grown in the media described above, replacing 10% FBS with 5% 
FBS and 10% human serum (Lonza). There are several reasons 
why we started with the cells from the healthy donors. First, we 
needed to study how the single ART drugs and then their com-
binations affect the gp41 expression on the cells. In real life, the 
patients are treated with at least triple combinations of drug, so 
that it would not be possible to delineate the effect of each drug. 
Second, we needed to investigate if the viral tropism affects the 
interaction between ART and gp41 expression. Isolated PBMCs 
at 2 ×  106  cells/mL were stimulated with phyto-hemagglutinin 
(PHA, Sigma) at 5 μg/mL and IL-2 at 10  U/mL for 48  h and 
then exposed for 3 h to either R5 HIVADA or X4 HIVNL4-3 virus at 
25 ng/mL as in Ref. (11). Cells were resuspended in fresh media 
with IL-2 and grown for 48 h at 37°C in 5% CO2 for infection to 
spread. Cells exposed to HIV are referred to as “infected” cells 
and those not exposed to the virus as “non-infected” cells as per 
the methodology described in our previous studies (6, 8).
suppression of hiV replication with arT
Peripheral blood mononuclear cells were cultured in a panel of 
ART drugs to titrate for optimal drug concentrations and show 
a dose–response of decreased HIV production with more drugs. 
TFV and FTC were initially tested at 0.001, 0.01, 0.1, 1, 10, and 
100 μM with the goal of spanning the entire range of potential drug 
concentrations. The ranges were derived from the EC50 values 
for each of the drugs, 0.04–8.5 μM for TFV and 0.0013–0.64 μM 
for FTC (9). Subsequent experiments were performed using the 
middle concentrations of 1 and 10 μM, which caused moderate to 
complete inhibition of HIV replication in vitro. For combination 
treatments, molarities of TFV and FTC were scaled relative to 
the typically prescribed milligram drug ratios, using 6:3:2 molar 
ratios of TFV/FTC/ATZ and 3:3:2 molar ratios of TFV/FTC/EFV. 
Final DMSO concentrations were below 0.5% per sample, which 
has no effect on the yield of infectious virus or cell growth rate 
(12). Freshly thawed ART drugs were added to 1 mL of media 
containing 10 IU/mL IL-2 and 106 cells. Cells were grown in low 
adhesion 24-well plates (Corning) in the presence of ART drugs 
for 6 days prior to treatment with 213Bi-2556, with the fresh media 
containing ART drugs and IL-2 given to cells on day 3.
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radiolabeling of 2556 mab
Clinical grade mAb 2556 against HIV-1 envelope glycoprotein 
gp41 was obtained from Goodwin Biotechnologies (Plantation, 
FL, USA). Control human mAb 1418 to parvovirus capsid VP1 
described in Ref. (13) was produced in the laboratory of Drs. 
Susan Zolla-Pazner and Miroslaw K. Gorny. The 2556 and 1418 
mAbs were conjugated to the chelating agent C-functionalized 
trans-cyclohexyldiethylenetriamine pentaacetic acid derivative 
(CHX-A″-DTPA) (Macrocyclics). 213Bi was obtained from a 
225Ac/213Bi generator produced at the Institute for Transuranium 
Elements (Karlsruhe, Germany) as in Ref. (14). The 2556 and 
1418 mAbs in carbonate buffer at pH 8.5 were incubated over-
night at room temperature with CHX-A″-DTPA using 10-fold 
excess of CHX-A″-DTPA over mAb on a molar basis (e.g., 
6.67 ×  10−8  mol CHX-A″-DTPA over 6.67 ×  10−9  mol mAb) 
and purified into 0.15M ammonium acetate buffer at pH 6.5 
using Vivaspin concentrators (Sartorius). Radiolabeling of 2556 
with 213Bi was accomplished by eluting 213Bi from the generator 
with 1 mL 0.1M HI solution, adjusting the pH of the eluate to 
4.5 with 2.5M ammonium acetate, incubating 213Bi containing 
solution with the CHX-A″-DTPA-conjugated mAbs for 5 min 
at 37°C and quenching the reaction by adding 4 μL of 0.01M 
EDTA. The radiolabeling yields and purity were >95% as 
determined by instant thin layer chromatography (ITLC). The 
immunoreactivity of the radiolabeled 2556 was determined by 
gp41 ELISA as in Ref. (8) and was >90% of the immunoreactiv-
ity of the naïve 2556. The specific activity of the radiolabeled 
mAbs was kept constant at 185 MBq/mg antibody throughout 
the study.
Quantification of gp41 expression  
on arT-Treated infected cells
The Scatchard transformation of the binding data was performed 
as described in Ref. (8, 15) to quantify gp41 expression on infected 
PBMCs cultured in ART. We radiolabeled 2556 mAb with 188Re in 
place of 213Bi to avoid killing of cells by 213Bi during the binding 
and the difficulties in correctly measuring radioactivity several 
times during the experiment as 213Bi quickly decays with the half-
life of 46  min. Five million cells per condition were incubated 
with increasing quantities of 188Re-2556 mAb (from 0.45 to 3 ng 
mAb per sample). The ratio of bound to unbound radioligand was 
plotted to identify the number of cellular binding sites from the 
x-intercept of the transformed Scatchard plot and the Ka constant 
from the ratio of y and x intercepts. The immunoreactivity of the 
radiolabeled antibody used in Scatchard experiments was >90% 
of the naïve 2556 as determined by gp41 ELISA (8). The experi-
ments were performed four times with every sample in triplicate. 
FACS was used to confirm gp41 expression by staining 106 cells 
with LIVE/DEAD Fixable Violet Dead Cell Stain Kit (Invitrogen) 
and with 2556 mAb at 20 μg/mL concentration directly labeled 
with Alexa Fluor 633 Protein Labeling Kit (Invitrogen).
Treatment of ach-2 cells and PBMcs  
with 213Bi-2556 mab
Following 6 days of culture in the presence of ART, the population 
from each sample well was resuspended in PBS and split equally 
between three 1.5-mL microcentrifuge vials (Fisher  Scientific) 
with 330,000 cells/vial as in Ref. (6, 8). The first two vials in 
each set were treated with varying activities of 213Bi-2556 mAb 
(0–0.370 MBq/mL) and the third vial with an equivalent volume 
of PBS (“untreated”). After addition of the radiolabeled mAb, 
the total volume of each sample was adjusted to 1 mL with PBS. 
When applicable, the irrelevant mAb 1418 (13) labeled with 213Bi 
was used as a control to measure non-specific killing. The cells 
were irradiated in pellets which were formed by cells settling 
under the gravity. After 3 h at 37°C, the tubes with the cells were 
spun, unbound antibody removed (at this stage, almost all 213Bi 
has decayed), and the cells resuspended in their appropriate 
media with IL-2 (PBMCs) or PMA (ACH-2 cells) and cultured in 
96-well plates (Fisher Scientific) at ~300,000 cells per well for 72 h 
at 37°C. Media did not contain ART drugs to allow for recovery 
of viral production by any surviving HIV-infected cells. All drug 
conditions were performed in duplicate and controls in triplicate.
assessment of In Vitro 213Bi-2556 efficacy
The number of viable cells in the samples before and after treatment 
with 213Bi-2556 was assessed electronically using the Cellometer 
Auto 2000 Cell Viability Counter (Nexcelom Bioscience) and 
validated manually with a hemocytometer using the Trypan blue 
dye exclusion (16). Within each ART condition, the low-activity 
and high-activity 213Bi-2556 conditions were compared to 0 MBq 
to determine absolute and relative percent killing by 213Bi-2556, 
ART, and their combination. Viral titers in each well supernatant 
were measured by a well-validated (17) commercial double anti-
body sandwich enzyme immunoassay kit for HIV-1 p24 ELISA 
(Advanced Bioscience Laboratories), which detects the presence 
of the HIV-1 viral core p24 gag antigen with a detection limit 
of 3.1 pg/mL. The positive controls were serial dilutions of the 
manufacturer-provided HIV-1 p24 standard containing purified 
HIV-1 IIIB p24. Enzyme-linked absorbance was fit to a known 
HIV-1 IIIB p24 standard curve, and sample p24 concentration 
was determined from linear regression analysis. Samples were 
scored as undetectable when the measured absorption was below 
that of negative controls wells containing complete culture media.
statistical analyses
Statistical significance for cell killing and p24 production was 
determined using a repeat measure two-way ANOVA compar-
ing the significance of the RIT-induced effect within each ART 
drug condition relative to the “0 MBq Bi-2556” control wells for 
that condition, using the Dunnett adjustment for multiple com-
parisons. P = 0.05 was set a priori as the threshold for statistical 
significance. The multiplicity-adjusted P values were reported for 
each comparison.
selection of Patient samples
Participants were recruited at the Montefiore AIDS Center out-
patient clinic. HIV-infected PBMCs were isolated as described 
above from 40-mL blood samples following Montefiore Medical 
Center IRB #2011-1100. Five patients were recruited for each 
of the 2 combination ART regimens [TFV/FTC/EFV and TFV/
FTC/ATZ/ritonavir (RTV)] along with 5 ART-naïve patients 
for a total of 15 patients. Within each ART group, three patients 
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had well-controlled infections (undetectable HIV RNA) and 
two had poorly controlled infections (HIV RNA >1000 copies/
mL). In the ART-naïve group, two patients had well-controlled 
infections (<10,000 copies/mL) and three had poorly controlled 
infections (>20,000 copies/mL). Patients with known substance 
abuse, resistance to their currently prescribed ART drugs, and 
elite controllers (<50  copies/mL sustained without ART) were 
excluded from the study.
assessment of Ex Vivo 213Bi-2556 efficacy
Peripheral blood mononuclear cells were isolated from par-
ticipants’ samples within 2  h of blood collection, treated with 
0–0.74 MBq 213Bi-2556 mAb at 0–0.74 MBq/mL concentration, 
and analyzed in 3 days for cell survival using Trypan blue exclu-
sion. Additionally, six participants’ samples were treated with 
radiolabeled control mAb 1418 (one patient from each ART-
treated group and four from the ART-naïve group). Quantitative 
RT-PCR was used to determine viral levels immediately before 
213Bi-2556 treatment and in the supernatants post-RIT. Samples 
were analyzed in duplicate on the Abbott m2000 RealTime HIV-1 
assay PCR machine (Abbott Laboratories), which detects the 
integrase region of the HIV-1 pol gene down to 40 RNA copies/
mL. The 100 μL of patient serum was used per sample. Machine 
readout was a numerical value, or undetectable RNA, or “RNA 
present but below detection limit,” which covers a range of 0–40 
copies/mL. For the last category, values were conservatively 
estimated at the limit of detection (LOD) of 40 copies/mL which 
converted to 400 copies/mL. Values reported are the mean of two 
duplicate conditions, processed separately.
calculations of the Projected  
human Dose of 213Bi-2556 mab
We performed the calculations of the projected human dose 
of 213Bi-2556 mAb by two different methods. The first method 
utilized the results of treating ex vivo PBMCs from patients on 
various ART regimens. For the ex vivo calculations, we used the 
following numbers: every patient donated 40 mL of blood from 
which 5 × 107 PBMCs were isolated. We used 3 × 105 PBMCs per 
sample to treat with 213Bi-2556. The lowest activity of 213Bi-2556 
to kill significant percentage of infected cells was 0.037  MBq; 
thus, to achieve this result for 5 ×  107 PBMCs, one needs (0.0
37 MBq × 5 × 107/3 × 105) = 6.17 MBq. An adult’s blood vol-
ume is approximately 5000 mL (5 L); so to treat the PBMCs in 
5 L of blood, one will need (6.17 MBq × 5000/40) = 771 MBq 
213Bi-2556. This number can be also expressed as MBq/kg, in 
which case for a 60-kg person, it will be 771/60 = 12.8 MBq/kg.
For comparison, we also performed the calculations using 
alternative strategy by using our previously published data on treat-
ing HIV in mouse models with 213Bi-2556 mAb (8). Interspecies 
scaling factor between mice and humans is equal to 12.3, which 
reflects 12.3-fold difference in surface area to body weight ratio 
for a mouse (0.0066 m2/0.02 kg) as compared to that for a human 
(1.6  m2/60  kg) (18). Consequently, 12.3 times more drug is 
required in the mouse to be comparable to the dose in humans. 
From our RIT of HIV mouse work, we know that HIV-infected 
hPBMCs in mice were eliminated in peritoneal model with 
3.7 MBq 213Bi-2556 (mAb) (8). Thus, the radioactivity for a mouse 
per kg body weight is calculated as 3.7 MBq/0.02 kg = 185 MBq/
kg. Accordingly, for a human taking into consideration 12.3 as 
conversion factor, it will be 185/12.3  MBq/kg =  15.0  MBq/kg. 
For a 60-kg human, the total radioactivity of 213Bi-2556 will be 
60 × 15.0 = 900 MBq. To calculate the amount of “cold” 2556 mAb 
in the radiolabeled preparation, the calculations were performed 
in the same fashion as given above using the following numbers: 
mAb dose in a mouse 0.02 mg/0.02 kg = 1 mg/kg; mAb dose in 
a human 1/12.3 = 0.08 mg/kg; and total “cold” 2556 mAb dose 
for a 60-kg human 0.08 × 60 = 4.8 mg. All calculations assumed 
a specific activity of 185 MBq/mg antibody for the radiolabeled 
antibody, which was used in all experiments in this manuscript 
and in the previous work (8).
resUlTs
gp41 is Present on arT-Treated  
hiV-infected cells
Our initial goal was to ascertain whether ART would decrease the 
gp41 expression on the surface of ART-treated infected cells. To 
the best of our knowledge, the expression of gp41 on ART-treated 
HIV-infected cells has not been quantified; however, given that 
ART interferes with viral replication, there is a concern that 
gp41 might be reduced (19) or even absent on the cell surface. 
We treated the ACH-2 human lymphocyte cell line (chronically 
infected with X4 HIVIIIB) with three major NRTIs and examined 
the gp41 expression by FACS and the viral load by p24 ELISA. 
The following drugs were used in biologically relevant concen-
trations (0.001–1.0 μM): TFV (adenosine analog), FTC (cytidine 
analog), the 3:2 combination of TFV:FTC (a common backbone 
of ART combination treatment), and zidovudine (AZT, thymi-
dine analog). FACS analysis of ACH-2 cells after exposure to 
ART demonstrated that the number of gp41-positive cells in the 
ART-treated samples was 5–40% of the number of gp41-positive 
cells in untreated population, and this decrease correlated with 
decrease in viral p24 production (Figure 1A). This observation 
established that significant numbers of ART-treated cells remain 
gp41-positive. The ART drug treatments had no effect on auto-
fluorescence compared to control cells, and therefore, the values 
are compared to uninfected control cells. This was supported by 
results of killing experiments in which the ACH-2 and parental 
HIV-negative A3.01 cells were treated individually, and in a 1:10 
combination with 0, 0.074, and 0.37 MBq/mL 213Bi-2556 mAb. 
The ACH-2 cells were mixed with the parental non-infected cells 
A3.01 in 1:10 ratio to demonstrate the specificity of killing of 
infected ACH-2 by radiolabeled 2556 mAb versus non-infected 
cells. 213Bi-2556 killed significantly more infected ACH-2 cells 
than uninfected A3.01 cells (Figure  1B) and decreased p24 to 
undetectable levels (Figure 1C). It is important to point out that 
as 2556 mAb binds also to gp41 on the viral particles (8), the non-
infected cells with some viral particles getting attached to their 
surface can also be killed by radiation, which results in increased 
overall cell kill. In addition, since this is the first study of the ART 
and RIT combination for treatment of the HIV-infected cells, we 
used a broad range of ART and RIT concentrations to identify 
the maximum tolerated doses. In case of RIT, 0.37 MBq/mL of 
A B
DC
FigUre 1 | 2556 mab binding and killing of hiV-infected cells lines. (a) FACS analysis of 2556 binding to ACH-2 cells. Uninfected parental cell line A3.01 was 
used as a negative control. FTC – emtricitabine, TFV – tenofovir, and AZT – zidovudine; (B) 213Bi-2556 mAb treatment of stimulated ACH-2 cells and parental A3.01 
cells, individually and in 1:10 combinations; and (c) p24 levels decreased post-RIT in both the combination and ACH-2 alone conditions, with no p24 detected in 
the control A3.01 samples. All cells were incubated with 213Bi-labeled mAbs for 3 h before being plated for survival. The error bars show SD; experiment was 
performed three times; * denotes statistically significant P value of <0.05 compared to 0 MBq in each ART group. The cell survival was measured 72 h post-
treatment. (D) Scatchard analysis of 188Re-2556 binding to HIVADA-infected PBMCs with and without ART treatment. No significant binding was detected on the 
uninfected PBMCs.
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213Bi-2556 mAb was five times higher than 0.074 MBq/mL and 
produced some off-target toxicity.
Quantification of gp41 expression on the 
arT-Treated hiV-infected cells
Scatchard analysis of radiolabeled 2556 mAb binding was 
used to quantify gp41 expression on the surface of PBMCs 
infected with R5-tropic strain HIVADA and treated with TFV, 
FTC, the PI ATZ, and the NNRTI EFV. Scatchard analysis 
revealed that ART-treated cells display over 104 gp41 binding 
sites per cell (Figure  1D): for ATZ-treated cells, the number 
was 5.7 ± 0.2 × 104 per cell; for EFV, 7.0 ± 0.4 × 104; for TFV, 
4.0 ± 0.3 × 104; and for FTC, 3.9 ± 0.4 × 104. These numbers are 
in the 40–70% range of 1.0 ± 0.2 × 105 binding sites on untreated 
cells. In cancer RIT studies where similar antigen levels on the 
surface of the targeted cells were observed in vitro (20, 21), the 
RIT was nevertheless successful in killing the targeted cells. 
Several sequential RIT administrations might be required, how-
ever, to eradicate all infected cells in an HIV patient. There was 
no significant binding of 2556 to uninfected PBMC controls. The 
binding constant for the 2556 binding to gp41 was not affected 
by the ART drugs and calculated to be 9.8 ×  107/M, which is 
very close to 1.1 × 108/M as in Ref. (8). We concluded that gp41 
expression on the surface of ART-treated cells is reduced but 
sufficient for the radiolabeled mAb to bind and deliver cytocidal 
radiation to the infected cells.
no significant Killing of Uninfected 
PBMcs by 213Bi-2556 or infected PBMcs 
by control mab 213Bi-1418 Was Observed
There was no statistically significant killing by 213Bi-2556 of 
uninfected ART-treated PBMCs (Figure 2A). This indicated that 
killing with 213Bi-2556 was HIV-specific and ART has neither 
radioprotective nor radiosensitizing effect. The specificity of 
213Bi-2556 was further confirmed by the absence of killing of 
infected and uninfected PBMCs by 213Bi-labeled irrelevant 1418 
mAb to parvovirus VP1 capsid protein (13) (Figures 2B,C). The 
1418 is a fully human 1gG1 mAb and was used as a control mAb 
in our previous work on RIT of HIV-infected cells and showed 
no killing of HIV-infected cells (6, 8). 213Bi-2556 might possess 
some cross-reactivity with the cellular membrane proteins, which 
FigUre 2 | PBMc-negative control experiments. (a) Uninfected PBMCs were neither killed by ART alone nor by co-administration of ART and 213Bi-2556 at the 
maximum concentration of each drug (10 μM); (B) 213Bi-2556 treatment of infected PBMCs results in significantly higher killing than either 213Bi-2556 treatment of 
uninfected PBMCs or infected PBMCs treated with radiolabeled irrelevant 1418 mAb; and (c) 213Bi-2556 eliminates detectable p24 at higher concentrations, in 
contrast to 213Bi-1418. All cells were incubated with 213Bi-labeled mAbs for 3 h before being plated for survival. The cell survival was measured 72 h post-treatment. 
The error bars show SD; experiment was performed two times; * denotes statistically significant P value of <0.05 compared to 0 MBq in each ART group.
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would result in it being “stickier” that 213Bi-1418 mAb and causing 
more killing of uninfected PBMCs than 213Bi-1418, though the 
difference was not statistically significant.
213Bi-2556 Killed arT-Treated PBMcs 
infected with Different Viral strains  
of hiV in a Dose-Dependent Manner
The experimental schema for these experiments is shown in 
Figure 3A. There are several reasons why we started with the 
cells from the healthy donors. First, we needed to study how 
the single ART drugs and then their combinations affect the 
gp41 expression on the cells. In real life, the patients are treated 
with at least triple combinations of drug, so that it would not 
be possible to delineate the effect of each drug. Second, we 
needed to investigate if the viral tropism affects the interaction 
between ART and gp41 expression and when the patients are 
recruited into the study, their viral strain is not known. On the 
contrary, we were able to infect the cells with either R5 or X4 
viruses with different tropism. 213Bi-2556 killing of X4 HIVNL4-
3-infected cells treated with FTC, TFV, or their combination 
occurred in a dose-dependent manner (Figures S1A–C in 
Supplementary Material), with the majority of infected cells 
in all ART conditions eliminated by 0.150 MBq/mL 213Bi-2556 
mAb (Figure 3B). A corresponding decrease in viral load post-
RIT was observed by p24 ELISA for all samples (Figure 3C). We 
also examined the RIT of cells infected with R5-tropic HIVADA 
strain. Dose-dependent cell killing by 213Bi-2556 was accompa-
nied by considerable reduction in viral load for HIVADA-cells 
treated with the FTC and TFV (Figures 4A,B). In cells exposed 
to higher doses of 213Bi-2556 and combined FTC/TFV, the post-
treatment viral load was undetectable. It should be noted here 
that the absence of p24 in the supernatant is a clear indication 
that there are no infected cells left, as p24 is a fragile protein 
which cannot survive several days in culture medium at 37°C 
(22). To further simulate the clinically relevant ART drug 
combinations, we combined FTC and TFV with either ATZ 
(Figures 4C,D) or EFV (Figures 4E,F). HIV-infected cells in 
both combinations were killed in a dose-dependent manner; 
however, the combination with EFV was more effective than 
with ATZ in completely eliminating infected cells at higher 
doses of ART and 213Bi-2556. Taken together, these results 
demonstrated that for cells infected with different viral strains, 
pretreatment with ART does not impede the killing with 213Bi-
2556 and provided the impetus for ex vivo RIT of PBMCs from 
HIV-infected individuals.
FigUre 3 | Killing of PBMcs infected with X4 hiVnl4-3 strain and treated with nrTis. (a) Design of ART and RIT combination experiments; (B) post-RIT 
survival of PBMCs treated with TFV, FTC, or TFV:FTC = 3:2. Shown are averages of two duplicate conditions per ART concentration, five concentrations per ART 
drug. Sixteen replicates per RIT dose; (c) post-RIT p24 analysis of high and moderate ART conditions from each treatment group. All cells were incubated with 
213Bi-labeled mAbs for 3 h before being plated for survival. The cell survival was measured 72 h post-treatment. The error bars show SD; experiment was performed 
three times; * denotes statistically significant P value of <0.05 compared to 0 MBq for each ART group.
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213Bi-2556 Treatment of Ex Vivo Patient 
samples Was effective in Killing infected 
cells and Decreasing the Viral load
Fifteen study participants were recruited including those with 
well- and poorly controlled infection: five for each of the two 
ART regimens TFV/FTC/EFV and TFV/FTC/ATZ/ritonavir 
(RTV) and five ART-naïve patients (Table 1). The three groups 
were similar in age: the mean age was 43.6, 42.4, and 40.6 years for 
the TFV/FTC/EFV, TFV/FTC/ATZ/RTV, and ART-naïve groups, 
respectively (P = 0.1). The mean time from the diagnosis was the 
6.0, 9.8 and 11.0 years in ART-naïve, TFV/FTC/EFV and TFV/
FTC/ATZ/RTV groups, respectively. The difference in the mean 
time from the diagnosis was significant between ART-naïve and 
TFV/FTC/EFV groups (P = 0.04) and between ART-naïve and 
TFV/FTC/ATZ/RTV groups (P = 0.02) but was not significant 
between the two ART-treated groups (P = 0.08). PBMCs isolated 
from the participants’ samples were treated with 0–0.74 MBq/mL 
213Bi-2556 mAb and analyzed for cell survival and residual viral 
production (Figure S2A in Supplementary Material). Additionally, 
six samples were treated with 0–0.74 MBq/mL radiolabeled con-
trol mAb 1418 to ascertain the specificity of killing by 213Bi-2556 
mAb. Dose-dependent killing of infected cells with 213Bi-2556 was 
observed for all participants in all three groups (Figures S2B–D 
in Supplementary Material). Overall, the treatment success was 
observed to be greater in the ART groups than in the ART-naïve 
group. However, we did not perform statistical comparisons 
between the groups due to the small number of study participants. 
The 213Bi-2556 mAb was specific as substantially less killing was 
seen with 213Bi-1418 control across all cohorts (Figure 5). Some 
killing seen with 213Bi-1418 was caused by random hits of emitted 
radioactive particles. The lymphocytes are some of the most radio-
sensitive cells in the body, and non-specific killing is unavoidable 
for in vitro assays performed in small volumes, but in vivo the 
side effects of 213Bi-2556 treatment were not observed (8). While 
side effects of RIT for cancer treatment may include transient and 
long-term myelodysplasia, neutropenia, and thrombocytopenia, 
the net safety record of RIT is strong particularly in comparison 
TaBle 1 | Demographic characteristics and hiV infection parameters of 
the study participants.
Patient age gender Years since  
diagnosis
cD4/ml Viral rna  
copies/ml
arT-naïve
Well-controlled
DT11 49 F 20 1418 951
DT15 27 F 1 416 2254
Poorly controlled
DT04 27 M 4 986 57,301
DT08 51 M 1 304 30,876
DT09 49 M 4 682 48,558
TFV/FTc/eFV
Well-controlled
DT02 54 F 10 784 Not detected
DT07 34 M 1 549 Not detected
DT14 24 F 7 870 Not detected
Poorly controlled
DT12 59 M 22 356 1287
DT13 47 M 9 468 2507
TFV/FTc/aTZ/rTV
Well-controlled
DT01 53 M 3 986 Not detected
DT05 45 F 15 669 Not detected
DT06 36 M 17 681 Not detected
Poorly controlled
DT03 53 M 14 22 36,453
DT10 25 M 6 334 39,902
FigUre 4 | Post-riT killing and p24 analysis of r5 hiVaDa-infected PBMcs treated with 3:2 combinations of TFV:FTc (a,B) or with the addition of 
atazanavir (c,D) or efavirenz (e,F). Atazanavir and efavirenz were each used at 10 μM and the ATZ:TFV:FTC and EFV:TFV:FTC molarities in (c–F) were scaled 
relative to the typically prescribed ratios of 6:3:2 and 3:3:2, respectively. All cells were incubated with 213Bi-labeled mAbs for 3 h before being plated for survival. The 
cell survival was measured 72 h post-treatment. The error bars show SD; experiment was performed four times; * denotes statistically significant P value of <0.05 
compared to 0 MBq in each ART group.
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with the high morbidity and low success rates of HIV gene therapy 
approaches (23). An HIV-infected patient would be more vulner-
able to the negative effects of myelosuppression than a healthy 
individual and should be monitored closely post-treatment, but 
the similarly vulnerable populations of cancer patients were 
treated with RIT with only transient myelosuppression (24, 25).
The data in Table  1 on patients’ treatment and viral loads 
served as the basis for patients’ selection for a particular cohort 
in the study. As the number of patients in the study was small, it 
would be impossible to make any correlations between the length 
the patients been on ART and their response to RIT. The patients 
with the undetectable viral loads are considered fully suppressed 
and there were six patients like this during the initial selection. 
Because the patients might experience lessening or improvement 
in viral control during the time past between their last blood test 
and RIT, we performed RT-PCR on their PBMCs immediately 
after their blood was donated for RIT and after the intermediate 
(0.15 MBq/mL) and high (0.74 MBq/mL) RIT activities (Table 2). 
The discrepancy between the well or poorly control status was 
observed for only for two patients – DT03 and DT15. Patient 
DT03 who was recruited as poorly controlled in TFV/FTC/ATZ/
RTV cohort became well controlled probably due to the improved 
compliance, while a well-controlled ART-naïve patient DT15 
experienced the lessening of the viral control, which is not unusual 
in ART-naïve patients. Importantly, the amount of virus detected 
FigUre 5 | Killing of PBMcs derived from arT-treated patients per 
treatment group (n = 5 per group) by 213Bi-2556 compared with killing 
by the 213Bi-labeled irrelevant control mab 1418 (six replicates per 
condition were used). All cells were incubated with 213Bi-labeled mAbs for 
3 h before being plated for survival. The cell survival was measured 72 h 
post-treatment. EFV combo – TFV/FTC/EFV; ATZ combo – TFV/FTC/ATZ/RTV.
TaBle 2 | Patient viral levels post-riT with 213Bi-2556 mab  
(rna copies/ml).a
Patient 0 MBq/ml 0.15 MBq/ml 0.74 MBq/ml
arT-naïve
Well-controlled
DT11 Not detected Not detected Not detected
DT15 31,860 50,770 35,355
Poorly controlled
DT04 44,702 18,300 13,883
DT08 257,040 108,735 5480
DT09 113,670 138,075 4425
TFV/FTc/eFV
Well-controlled
DT02 288 Not detected Not detected
DT07 <400b Not detected Not detected
DT14 Not detected 250 Not detected
Poorly controlled
DT12 18,420 <400b Not detected
DT13 8245 2795 325
TFV/FTc/aTZ/rTV
Well-controlled
DT01 Not detected Not detected <400b
DT05 310 Not detected Not detected
DT06 Not detected Not detected Not detected
Poorly controlled
DT03 <400b <400b <400b
DT10 49,775 14,890 Not detected
Values reported are the mean of two duplicate conditions, processed separately.
a0, 0.15, and 0.74 MBq/mL 213Bi-2556 were used. The radiochemical purity of 213Bi-
2556 mAb was 95%, the specific activity 185 MBq/mg, and the immunoreactivity 93%.
bFor the marked samples, the Abbott m2000 readout “RNA present but below 
detection limit” was conservatively estimated at the limit of detection of 40 copies/mL 
and adjusted to 400 copies/mL with dilution factor.
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in the treated samples decreased, often to undetectable levels, in 
14 of 15 ex vivo samples (Table 2). No decrease in viral load was 
observed in the DT15 participant who was initially recruited as 
an ART-naïve with well-controlled viremia (Table 1). A possible 
explanation for the increase in viral RNA copies/mL post-RIT in 
this patient could be that the cells killed by 213Bi-2556 released 
viral particles as the cells were dying from radiation-induced 
apoptosis without ART drugs. This observation highlights the 
importance of continuing maintenance on ART during RIT to 
prevent the re-infection of cells by the released viral particles.
Finally, we calculated the activity of 213Bi-2556 mAb for an 
HIV-infected individual to achieve the same degree of infected 
cell killing as observed ex vivo. Assuming that an adult’s blood 
volume is 5  L, the projected activity will be 740  MBq, which 
for a 60-kg person will be 740/60  =  12.3  MBq/kg. We also 
performed an alternative calculation using our data on treating 
HIV in mouse models with 213Bi-2556 (8) and the interspecies 
scaling factor between mice and humans. The calculated activ-
ity of 910 MBq (15.2 MBq/kg for a 60-kg person) was close to 
the activity calculated from the in vivo results. Using the same 
approach, the amount of the mAb in preparation was calculated 
to be 0.08 mg/kg. It is important to say that most likely in vivo 
there will be no “cross-fire” killing of the separately localized 
infected cells, and this is why the activity administered to a 
patient needed for complete elimination of the infected cells 
might be significantly higher than calculated here or even will 
have to be given several times. Of note, the projected patient dose 
calculated from the mouse experiments is higher than that from 
the in vitro experiments. The question of specific activity is also 
very important when the projected patient dose is discussed. For 
a specific activity of 185 MBq/mg, only 1 antibody out of 5000 
is radiolabeled, which means that 14 radiolabeled antibodies 
will be attached to each cell. This will result in seven particles 
crossing the cell but, on average, only one alpha particle will cross 
the nucleus (considering the probability of 0.067 to cross the 
nucleus when the cell is 10 μm in radius and the nucleus is 5 μm 
in radius). Thus, increasing specific activity of the radioconjugate 
might be crucial for the success of RIT in HIV patients. In this 
regard, our on-going experiments show that 2556 mAb can be 
very reproducibly radiolabeled with 740 MBq/mg specific activity 
without losing its immunoreactivity (Dina Tsukrov, unpublished 
observations). Finally, it should be noted that such calculations 
can serve only as a theoretical estimate to compare a projected 
dose for an HIV patient to that of a cancer patients. In real clini-
cal situation, the individualized dose calculation will involve first 
imaging of a patient with immunoSPECT or immunoPET and 
taking into consideration his/her bone marrow reserve.
DiscUssiOn
Here, we describe the first experience of using RIT to treat ex vivo 
PBMCs from ART-treated and ART-naïve individuals, to evalu-
ate the killing efficacy of 213Bi-2556 with concurrent ART treat-
ment. There was a concern that ART would reduce the expression 
of the gp41 target protein on the infected cells to such levels that 
the radiolabeled mAb would not bind; however, the Scatchard 
analysis of the 2556 binding to the infected and ART-treated cells 
demonstrated sufficient residual expression of gp41 on the cell 
surface to warrant subsequent RIT. To the best of our knowledge, 
this is the first time the quantification of gp41 post-ART is being 
reported. Our results are indirectly confirmed by the recent 
report by Santangelo et al. who detected gp120 expression on the 
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SIV-infected cells in  vitro and in  vivo in averimic SIV-infected 
macaques on ART and in elite controllers alike (26).
213Bi-2556 alone eliminated most, but not all, of the detectable 
viral production according to p24 ELISA; however, the combina-
tion of ART and RIT completely eliminated detectable virus. Our 
results suggest that RIT would be most effective in the presence 
of ART. An additional benefit of using ART is the reduction of 
free virus in the blood stream (which would otherwise present 
additional gp41 targets) freeing the 213Bi-2556 to seek and kill 
infected cells. The killing results indicate that even when gp41 
expression is reduced by ART, there are binding sites on the 
surface of infected cells for the radiolabeled mAb to bind and kill 
HIV-infected cells. This observation is supported by cancer RIT 
data for cells with similar levels of antigen expression (20, 21, 25) 
and by RIT of Bacillus anthracis bacterial infection (27). A few 
alpha particles transversing a nucleus are considered capable of 
killing a cell (28, 29). It should be noted that percentage of HIV-
infected PBMCs in patients ranges from 0.6 to 20% (30). Due to 
the stationary nature of the killing assays utilized in this study, up 
to 30% of non-specific killing of PBMCs was observed in patients’ 
samples at the highest activity of 0.75 MBq/mL as measured with 
control mAb 213Bi-1418 (Figure 5). Such non-specific killing was 
not observed in vivo in mice carrying HIV-infected human cells 
and treated with RIT (6, 8).
Elimination of HIV-infected cells will necessarily constitute 
a backbone of any HIV eradication strategy. Currently, the 
dominant experimental strategy to eliminate infected cells is 
reactivation of latent HIV using agents such as histone deacety-
lase (HDAC) inhibitors (31). However, it is still unclear if such 
reactivation, accompanied by aggressive ART or other treat-
ments, will result in eradication of all the infected cells or in new 
infections. Gene disruption and bone marrow transplantation are 
investigated for their potential to cure HIV (32, 33), but these are 
risky and expensive procedures that are currently not feasible for 
the treatment of large numbers of patients. The success in oncol-
ogy of naked mAb therapy, immunotoxins [e.g., FDA-approved 
trastuzumab drug conjugate for metastatic breast cancer (34)], 
and RIT contributed to the renewed interest in HIV elimination 
strategies based on armed mAbs (35–37). The advantages of armed 
antibodies approach for HIV cure is the independence from the 
host immune system. Also, antibody–antigen interaction is not 
subject to multidrug resistance mechanisms. Significant deple-
tion of the systemic viral reservoir in BLT mice from combined 
ART and immunotoxin treatment was reported (38), although the 
challenges of complex chemistry and inherent immunogenicity 
remain to be resolved. A fully human mAb 213Bi-2556 used in this 
study possesses additional advantages of not being immunogenic, 
not requiring internalization, and having minimal toxicity due to 
213Bi 46 min half-life resulting in decay of a projected 740 MBq 
human dose to nearly undetectable levels (1% or 7.4  MBq) 
within 5 h of administration. 213Bi-labeled mAbs and peptides are 
in clinical trials for several oncological indications, both as the 
primary therapy and in combination with prior chemotherapy 
(39–41). The projected activity for a human of 12.3 MBq/kg is 
close to ~1.0  GBq cumulative activity of 213Bi-HuM195 mAb 
given to patients with acute myeloid leukemia (39). Generally, 
injection of 213Bi immunoconjugate induces some hematologic 
toxicity in patients, for example, on leukocyte and red blood cell 
(42, 43). It remains to be seen if the lack of toxicity in vitro in this 
study will be observed in patients as well.
The use of targeted therapy with α-particle emitters is bur-
geoning worldwide, driven by the advantages of α-emitters over 
β-emitters including specific targeting of the diseased cells due to 
the α-particles’ short 50–80 μm tissue range and increased kill-
ing efficiency due to high linear energy transfer (44). It has been 
demonstrated experimentally that RIT with α-emitters does not 
depend on the oxygenation status of the tumor or its resistance 
to chemo and external beam radiation therapy (45, 46) and later 
confirmed clinically by achieving 213Bi-labeled peptide-induced 
remission in patients with neuroendocrine tumors refractory 
to β-radiation (43). Clinical trials of 213Bi targeted therapy are 
conducted in tertiary hospitals by performing “bedside manufac-
turing” (see Supplementary Material) and can easily be adopted 
for HIV patients. RIT can be combined with the immunoPET 
imaging, which would add new dimension to the developing 
of HIV curative drugs and to studying the mechanisms of HIV 
pathogenesis (47).
While we do not anticipate 2556 mAb-binding interference 
from the fusion inhibitors, maraviroc and enfuvirtide, which 
bind gp41 later in the viral life-cycle than 2556 mAb, and in a dif-
ferent region of gp41, they will be an important category of ART 
drugs to explore in the future trials. Our results using PBMCs 
from HIV-infected individuals suggest that complete eradica-
tion of HIV-infected cells is likely to require more than one RIT 
administration. A major challenge that remains is to eradicate 
latently infected cells. Studies in non-human primates to test RIT 
in combination with ART are planned.
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